Back to Archived News
BIOLASE Issued Broad New Patent for Treating Eye Conditions, Including Presbyopia, Cataracts and Glaucoma
Wednesday, November 30, 2011
Irvine, CA -- BIOLASE Technology, Inc., the World's leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has issued BIOLASE a new patent covering the use of its laser technologies for treating various conditions of the eye. The patent covers the architecture and techniques for treating an ocular or related tissue site utilizing laser energy to affect one or more physiological properties mitigating the effects of presbyopia and improving the way a person sees.
Patent 8,056,564 is titled "Methods for Treating Eye Conditions" and supports the ophthalmic patents previously issued to BIOLASE by expanding the application of the laser beyond the conjunctiva and sclera to ocular or other related tissue sites. This new patent not only covers methods to treat presbyopia, but it is also applicable to a broad range of other eye conditions, including glaucoma, retinal disorders, and cataracts.
This is the ninth U.S. patent issued under the "Methods for Treating Eye Conditions" patent family with two international patents also issued. BIOLASE currently holds a total of 15 issued and 20 pending U.S. and International patents in five patent families in the field of ophthalmology. These patents give BIOLASE and its wholly-owned subsidiary, OCCULASE, Inc., the widest range of potential applications and coverage in the field.
Federico Pignatelli, Chairman and CEO, commented, "This patent further demonstrates how broad the applications for our patented laser technologies are within ophthalmology. We are assessing a number of strategic alternatives for our valuable ophthalmology technology embodied in the Er,Cr:YSGG OCCULASE MD laser system that we are currently working to commercialize under our OCCULASE subsidiary. In addition to ophthalmology, we are evaluating several other major medical applications in orthopedics, aesthetics, dermatology, ENT, podiatry and pain management for our laser technologies."
About BIOLASE Technology, Inc. BIOLASE Technology, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com , Twitter at http://twitter.com/GoWaterlase , and YouTube at http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
Back to Archived News